Skip to main content
Selvita S.A. logo

Selvita S.A. — Investor Relations & Filings

Ticker · SLV ISIN · PLSLVCR00029 LEI · 25940057WQ9YP5MOQF28 WAR Professional, scientific and technical activities
Open in API
Filings indexed 1,179 across all filing types
Latest filing 2022-10-14 Report Publication Anno…
Country PL Poland
Listing WAR SLV

About Selvita S.A.

https://selvita.com/

Selvita S.A. is a preclinical contract research organization (CRO) providing integrated services for the pharmaceutical and biotechnology sectors. The company offers comprehensive solutions across the drug discovery and development continuum, from target validation to preclinical candidate nomination. Core drug discovery capabilities include medicinal chemistry, pharmacology, DMPK, and protein sciences, supporting a wide range of modalities such as small molecules, antibodies, and protein degraders. For drug development, Selvita provides analytical support for small and large molecules, formulation, microbiology services, and manufacturing for clinical trials. The company operates under GMP and GLP quality standards, offering flexible engagement models that range from standalone studies to fully integrated programs.

Recent filings

Filing Released Lang Actions
Korekta raportu okresowego za I półrocze 2022 r. / Amendment to the H1 2022 periodic report - Content (EN)
Report Publication Announcement Classification · 99% confidence The document explicitly states that it is informing about an 'amendment to the consolidated periodic report for the first half of 2022 ("H1 Report")' which was previously published. It details the specific statements that were omitted and are now being added. Since the document is an announcement about correcting/amending a previously issued report (the H1 Report), and it is short (1543 chars) and states the 'amended H1 Report containing the above statements is attached hereto,' it fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive Interim Report (IR) itself. The content is an administrative update regarding a prior filing.
2022-10-14 English
Korekta raportu okresowego za I półrocze 2022 r. / Amendment to the H1 2022 periodic report - Content (PL)
Report Publication Announcement Classification · 99% confidence The document is a formal announcement by the Management Board ('Zarząd') of Selvita S.A. regarding a correction ('korekty') made to their periodic report for the first half of 2022 ('Raport H1'). The correction involves adding mandatory statements from the Management Board required by Polish financial regulations (§ 68 and § 69 of the Minister of Finance regulation). Since the document is an announcement about a correction to a previously issued semi-annual report, and the corrected report itself is attached or referenced as a separate filing, this filing primarily serves as a notification of a regulatory update or correction to a periodic report. Given the content focuses on mandatory statements within a semi-annual report context, it aligns closely with the scope of an Interim/Quarterly Report (IR). However, because the document itself is an announcement *about* the correction and the attachment is the corrected report, it could also be considered a Regulatory Filing (RNS) or a Report Publication Announcement (RPA) if it were very short. Since it details the specific nature of the correction (adding mandatory legal statements) related to a semi-annual report, classifying it as an Interim Report (IR) that has been subsequently corrected is appropriate, as the core subject matter relates to the comprehensive financial reporting period. Given the context of correcting a semi-annual report, IR is the most specific fit, although RPA/RNS are close alternatives if the focus was purely on the announcement mechanism.
2022-10-14 Polish
Otrzymanie istotnego zlecenia / Receipt of a significant purchase order - Content (EN)
Regulatory Filings Classification · 95% confidence The document is a formal announcement by the Management Board of Selvita S.A. regarding a significant purchase order received by its subsidiary, Selvita d.o.o., from a major European pharmaceutical group. It details the nature of the services (ADME/DMPK), the increase in the order's value (EUR 1,400,000), and the total value of the contract. This type of announcement, concerning a material contract or significant business development that impacts the company's financial outlook or operations, typically falls under general regulatory disclosures. Since it is not a specific financial report (like 10-K, IR, ER), a management change (MANG), or a capital event (CAP, SHA), the most appropriate classification is the general regulatory filing category, RNS, as it is a material, non-standard announcement.
2022-10-03 English
Otrzymanie istotnego zlecenia / Receipt of a significant purchase order - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the Management Board ('Zarząd') of Selvita S.A. written in Polish. It references a previous report and details an expansion of a research services contract ('zlecenie rozszerzające zakres') with a major European pharmaceutical group. The core content is the announcement of a significant contract amendment, specifying the services (ADME/DMPK) and the resulting increase in contract value (EUR 1,400,000). This type of announcement, detailing a significant business transaction or contract award that impacts the company's operations or financial outlook, is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if it were about raising funds, but here it is about a service contract. Since there is no specific category for 'Significant Contract Award' and it is a formal regulatory disclosure, RNS is the most appropriate fallback. It is not an Earnings Release (ER), Interim Report (IR), or a specific management/board change notice (MANG). Given the nature of disclosing a material contract change, RNS is the best fit among the provided options.
2022-10-03 Polish
Powiadomienie o transakcji
Director's Dealing Classification · 100% confidence The document is a 'Standard form – Notification of transaction(s) referred to in Article 19(1) of the MAR for a person discharging managerial responsibilities'. This type of filing reports personal share transactions by company directors or senior management (a person discharging managerial responsibilities). This directly corresponds to the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The presence of 'Adrijana Vinter' as 'Członek Zarządu' (Management Board Member) confirms this is an insider transaction report.
2022-09-30 Polish
Powiadomienie od osoby pełniącej obowiązki zarządcze w Spółce w związku z realizacją Programu Motywacyjnego/Notification from person discharging managerial responsibilities in the Company due to ex...
Director's Dealing Classification · 98% confidence The document text explicitly mentions a notification received from a Management Board Member regarding the execution of a Stock Grant Program, referencing Article 19.1 of MAR (Market Abuse Regulation, common in EU filings). This type of transaction by an executive or director is classified as insider dealing or director's dealing. The filing category 'Director's Dealing (DIRS)' fits this description best, as it covers reports of personal share transactions by company directors and executives. The document is short and states 'The notification is attached to this report,' but the core content is the director's dealing notification itself, making DIRS more specific than RPA or RNS.
2022-09-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.